#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Cannabis hyperemesis syndrome represents an increasingly prevalent clinical entity that emergency and primary care providers must recognize to avoid unnecessary diagnostic workup and inappropriate treatment escalation in cannabis users presenting with cyclic vomiting. The dramatic rise in CHS cases over the past decade correlates with increased cannabis potency and frequency of use, making this differential diagnosis essential for reducing healthcare utilization and improving symptom management through cannabinoid cessation. Recognition of CHS’s characteristic presentation and reliable response to cessation can significantly decrease patient morbidity and emergency department burden while avoiding iatrogenic harm from prolonged antiemetic therapy.
Cannabis hyperemesis syndrome (CHS) is increasingly recognized across clinical practice, with reports of rising case numbers nationwide prompting heightened awareness among healthcare providers. CHS manifests as cyclic vomiting, abdominal pain, and nausea in heavy cannabis users, with symptoms paradoxically relieved by hot showers or baths, distinguishing it from other causes of hyperemesis. The rising incidence parallels increased cannabis potency and frequency of use, particularly among regular users consuming high-THC products, making CHS a clinically relevant diagnosis for emergency departments and primary care settings. Clinicians should maintain a high index of suspicion for CHS in patients presenting with refractory nausea and vomiting, particularly those reporting daily or near-daily cannabis use, as misdiagnosis often leads to unnecessary testing and delayed recognition of the underlying etiology. The primary management approach involves cessation of cannabis use, which typically results in symptom resolution, though supportive care and antiemetics may be needed during acute episodes. Healthcare providers should proactively counsel regular cannabis users about the risk of CHS and consider screening for cannabis use disorder in patients with recurrent unexplained hyperemesis to enable early intervention and symptom relief.
“Cannabinoid hyperemesis syndrome is a real and increasingly common condition we’re seeing in our clinics, particularly among daily cannabis users, and it demands the same diagnostic rigor and patient education we’d apply to any other substance-related disorder. The cycle of symptom relief through continued use followed by worsening symptoms creates a diagnostic trap that many patients and providers miss, which is why we need to ask directly about cannabis frequency and pattern in anyone presenting with recurrent nausea and vomiting.”
💊 Cannabinoid hyperemesis syndrome (CHS) appears to be increasing in frequency, likely reflecting both rising cannabis use and improved clinical recognition of this paradoxical condition in which heavy, chronic cannabis consumption triggers severe cyclic vomiting despite ongoing use. However, the true epidemiology remains unclear, as diagnostic criteria are not standardized across studies, reporting bias may inflate incidence estimates in academic centers, and the syndrome’s pathophysiology is incompletely understood, limiting our ability to identify high-risk users prospectively. Additionally, confounders such as concurrent substance use, underlying gastrointestinal disorders, and cannabis product potency and formulation differences complicate interpretation of causality in individual cases. Clinically, providers should maintain a high index of suspicion for CHS in patients presenting with refractory nausea and vomiting, particularly those using cannabis daily or multiple times per day, as early recognition and frank counseling
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: